Zvonimir Mlinarić
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zvonimir Mlinarić has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Miranda Sertić
Department of Pharmaceutical Analysis, Faculty of Pharmacy and Biochemistry University of Zagreb Zagreb Croatia
5 shared publications - Lu Turković
Department of Pharmaceutical Analysis, Faculty of Pharmacy and Biochemistry University of Zagreb Zagreb Croatia
4 shared publications - Biljana Nigović
Department of Pharmaceutical Analysis, Faculty of Pharmacy and Biochemistry, University of Zagreb, Ante Kovačića 1, 10000 Zagreb, Croatia
2 shared publications - Branka Zorc
Department of Medicinal Chemistry, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
2 shared publications - Zrinka Rajić
Faculty of Pharmacy and Biochemistry, University of Zagreb, A. Kovačića 1, 10000 Zagreb, Croatia
2 shared publications Ali Burak Özkaya
Faculty of Medicine İzmir University of Economics Türkiye
1 shared publication
Latest Publications
- Open Access
- 26 October 2026
- Published by Wiley in FEBS Open Bio
Design and evaluation of FEBS Education and Training Academy module – Integrating generative artificial intelligence into life‐science education
Generative artificial intelligence (AI) is now embedded in higher education. Yet educators often adopt it more slowly and cautiously than students, and generic guidance rarely translates into changes in teaching or assessment practice. We designed a short, hands‐on, pedagogy‐first workshop in which life‐science educators work with their own course materials, intended to increase confidence in pedagogically informed AI use and prompt concrete changes to course design, teaching and assessment. However, this is an exploratory feasibility and specification report; therefore, the evaluation was not designed to test that intention. Here we describe the design of a transferable three‐session FEBS Education and Training Academy module, organised around the PICRAT (Passive‐Interactive‐Creative/Replace‐Amplify‐Transform) framework, a four‐element prompt structure and studio‐style application to participants' own teaching artefacts, and evaluate it using matched pre/post surveys, anonymous after‐session feedback and an online follow‐up meeting. Thirty‐four educators from 14 countries attended; 21 completed the pre‐workshop and 13 the post‐workshop survey (12 matched). Among the 12 respondents who completed both surveys, the proportion reporting high confidence rose by the same margin, 4 of 12, in each of the five practical domains. Ten of 13 follow‐up respondents reported implementing at least one idea and while views of AI as beneficial were already positive and changed little, agreement that AI poses significant risks to academic integrity fell. These participant‐reported, uncontrolled findings should be read as evidence of feasibility and perceived usefulness rather than causal impact.
- 26 October 2026
- Published by Wiley in FEBS Open Bio
Open AccessDesign and evaluation of FEBS Education and Training Academy module – Integrating generative artificial intelligence into life‐science education
Generative artificial intelligence (AI) is now embedded in higher education. Yet educators often adopt it more slowly and cautiously than students, and generic guidance rarely translates into changes in teaching or assessment practice. We designed a short, hands‐on, pedagogy‐first workshop in which life‐science educators work with their own course materials, intended to increase confidence in pedagogically informed AI use and prompt concrete changes to course design, teaching and assessment. However, this is an exploratory feasibility and specification report; therefore, the evaluation was not designed to test that intention. Here we describe the design of a transferable three‐session FEBS Education and Training Academy module, organised around the PICRAT (Passive‐Interactive‐Creative/Replace‐Amplify‐Transform) framework, a four‐element prompt structure and studio‐style application to participants' own teaching artefacts, and evaluate it using matched pre/post surveys, anonymous after‐session feedback and an online follow‐up meeting. Thirty‐four educators from 14 countries attended; 21 completed the pre‐workshop and 13 the post‐workshop survey (12 matched). Among the 12 respondents who completed both surveys, the proportion reporting high confidence rose by the same margin, 4 of 12, in each of the five practical domains. Ten of 13 follow‐up respondents reported implementing at least one idea and while views of AI as beneficial were already positive and changed little, agreement that AI poses significant risks to academic integrity fell. These participant‐reported, uncontrolled findings should be read as evidence of feasibility and perceived usefulness rather than causal impact.
- 17 November 2025
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 418 (3) , 793-804
Surfactant-enhanced emulsification liquid-liquid microextraction combined with sweeping micellar electrokinetic chromatography-tandem mass spectrometry for therapeutic drug monitoring of alpelisib and fulvestrant in human plasma
A novel bioanalytical method combining surfactant-enhanced emulsification liquid-liquid microextraction (SE-LLME) with sweeping micellar electrokinetic chromatography-tandem mass spectrometry (MEKC-MS/MS) was developed and validated for therapeutic drug monitoring (TDM) of alpelisib (ALP) and fulvestrant (FUL) in human plasma. This method addresses the need for sensitive, selective quantification in patients with PIK3CA-mutated, HR+/HER2− breast cancer. Sample preparation involved protein precipitation followed by SE-LLME using pentadecafluorooctanoic acid (PFOA) and chloroform, yielding recoveries greater than 88.4% for ALP and 78.7% for FUL. Optimised MEKC conditions were 50 mM ammonium pentadecafluorooctanoate at pH 9.75 with 25% methanol, 30 kV separation voltage, 30 °C capillary temperature, and 100 mbar additional pressure during the analysis. Sweeping preconcentration significantly enhanced sensitivity—109-fold for ALP and 11.2-fold for FUL. The method was validated per ICH guidelines, demonstrating excellent linearity (\(r\ge\) 0.9963) across the calibration ranges (200–2000 ng/mL for ALP, 10–100 ng/mL for FUL), accuracy (mean biases −10.3% to 7.5%), and precision (RSD < 12.6%). Despite notable matrix effects for ALP, consistency across six different plasma sources (RSD ≤ 12.7%) ensured reliability. Analytes were stable under benchtop, autosampler, freeze-thaw, and long-term conditions (bias ≤ 11.1%). No carry-over was detected, and dilution integrity was confirmed (bias ≤ 2.7%). Application to patient samples validated the method’s clinical relevance, with measured concentrations aligning with the expected ones. This is the first capillary electrophoresis method for ALP in biological matrices and the only method for simultaneous TDM of ALP and FUL, offering a robust, cost-effective, and eco-friendly alternative to traditional chromatographic approaches. Graphical abstract- 17 November 2025
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 418 (3) , 793-804
Surfactant-enhanced emulsification liquid-liquid microextraction combined with sweeping micellar electrokinetic chromatography-tandem mass spectrometry for therapeutic drug monitoring of alpelisib and fulvestrant in human plasma
A novel bioanalytical method combining surfactant-enhanced emulsification liquid-liquid microextraction (SE-LLME) with sweeping micellar electrokinetic chromatography-tandem mass spectrometry (MEKC-MS/MS) was developed and validated for therapeutic drug monitoring (TDM) of alpelisib (ALP) and fulvestrant (FUL) in human plasma. This method addresses the need for sensitive, selective quantification in patients with PIK3CA-mutated, HR+/HER2− breast cancer. Sample preparation involved protein precipitation followed by SE-LLME using pentadecafluorooctanoic acid (PFOA) and chloroform, yielding recoveries greater than 88.4% for ALP and 78.7% for FUL. Optimised MEKC conditions were 50 mM ammonium pentadecafluorooctanoate at pH 9.75 with 25% methanol, 30 kV separation voltage, 30 °C capillary temperature, and 100 mbar additional pressure during the analysis. Sweeping preconcentration significantly enhanced sensitivity—109-fold for ALP and 11.2-fold for FUL. The method was validated per ICH guidelines, demonstrating excellent linearity (\(r\ge\) 0.9963) across the calibration ranges (200–2000 ng/mL for ALP, 10–100 ng/mL for FUL), accuracy (mean biases −10.3% to 7.5%), and precision (RSD < 12.6%). Despite notable matrix effects for ALP, consistency across six different plasma sources (RSD ≤ 12.7%) ensured reliability. Analytes were stable under benchtop, autosampler, freeze-thaw, and long-term conditions (bias ≤ 11.1%). No carry-over was detected, and dilution integrity was confirmed (bias ≤ 2.7%). Application to patient samples validated the method’s clinical relevance, with measured concentrations aligning with the expected ones. This is the first capillary electrophoresis method for ALP in biological matrices and the only method for simultaneous TDM of ALP and FUL, offering a robust, cost-effective, and eco-friendly alternative to traditional chromatographic approaches. Graphical abstract- Open Access
- 17 October 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (45) , 32876-32882
Development, cross-validation and greenness assessment of capillary electrophoresis method for determination of ALP in pharmaceutical dosage forms – an alternative to liquid chromatography
Breast cancer treatment has made tremendous progress in recent years and new therapies are emerging continuously. Alpelisib (ALP) is a novel phosphoinositide-3-kinase (PI3K) inhibitor recently approved for human receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutated metastatic breast cancer in combination with fulvestrant. ALP has been the subject of only a limited number of preclinical in vitro and in vivo studies using different chromatographic techniques. However, no research has been published on analyzing ALP using capillary electrophoresis (CE). The absence of pharmacopoeial monographs for ALP in both the European and United States Pharmacopoeias highlights the urgent need to develop a reliable analytical method for its quality control in both industry and regulatory authorities. In this work, we have developed a first-ever CE method for the determination of ALP in pharmaceutical dosage forms in just 1.4 minutes. This was achieved with a 25 mM borate buffer at pH 9.3, 30 kV separation voltage and 30 °C capillary temperature. The proposed method was validated according to the ICH guidelines regarding selectivity, linearity (r = 0.9988), precision (RSD < 5.9%), accuracy (bias < 3.0%) and robustness (RSD < 3.2%). It was applied to the pharmaceutical dosage form of ALP and was shown to be suitable for the reliable determination of ALP. Furthermore, to demonstrate the applicability of the CE as an alternative technique to more commonly used HPLC in the analysis of drugs, cross-validation of CE and HPLC methods was performed. Bland–Altman analysis showed that the average difference in determined concentrations between CE and HPLC over a range of 10–100 μg mL−1 was 0.87 μg mL−1 (p = 0.6390, N = 19) meaning that there is no difference in the performance of CE and HPLC in the determination of ALP in pharmaceutical dosage forms. The environmental impact of both methods was assessed using AGREE software and scores for CE and HPLC were calculated to be 0.74 and 0.51, respectively. Because of equally reliable analytical performance and greener analysis, CE should be considered as an alternative technique to HPLC in the analysis of ALP pharmaceutical dosage forms.
- 17 October 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (45) , 32876-32882
Open AccessDevelopment, cross-validation and greenness assessment of capillary electrophoresis method for determination of ALP in pharmaceutical dosage forms – an alternative to liquid chromatography
Breast cancer treatment has made tremendous progress in recent years and new therapies are emerging continuously. Alpelisib (ALP) is a novel phosphoinositide-3-kinase (PI3K) inhibitor recently approved for human receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutated metastatic breast cancer in combination with fulvestrant. ALP has been the subject of only a limited number of preclinical in vitro and in vivo studies using different chromatographic techniques. However, no research has been published on analyzing ALP using capillary electrophoresis (CE). The absence of pharmacopoeial monographs for ALP in both the European and United States Pharmacopoeias highlights the urgent need to develop a reliable analytical method for its quality control in both industry and regulatory authorities. In this work, we have developed a first-ever CE method for the determination of ALP in pharmaceutical dosage forms in just 1.4 minutes. This was achieved with a 25 mM borate buffer at pH 9.3, 30 kV separation voltage and 30 °C capillary temperature. The proposed method was validated according to the ICH guidelines regarding selectivity, linearity (r = 0.9988), precision (RSD < 5.9%), accuracy (bias < 3.0%) and robustness (RSD < 3.2%). It was applied to the pharmaceutical dosage form of ALP and was shown to be suitable for the reliable determination of ALP. Furthermore, to demonstrate the applicability of the CE as an alternative technique to more commonly used HPLC in the analysis of drugs, cross-validation of CE and HPLC methods was performed. Bland–Altman analysis showed that the average difference in determined concentrations between CE and HPLC over a range of 10–100 μg mL−1 was 0.87 μg mL−1 (p = 0.6390, N = 19) meaning that there is no difference in the performance of CE and HPLC in the determination of ALP in pharmaceutical dosage forms. The environmental impact of both methods was assessed using AGREE software and scores for CE and HPLC were calculated to be 0.74 and 0.51, respectively. Because of equally reliable analytical performance and greener analysis, CE should be considered as an alternative technique to HPLC in the analysis of ALP pharmaceutical dosage forms.
- Open Access
- 12 October 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (10) , 1445
Optimisation of Solid-Phase Extraction and LC-MS/MS Analysis of Six Breast Cancer Drugs in Patient Plasma Samples
In the development of bioanalytical LC-MS methods for the determination of drugs in plasma samples in a clinical setting, adequate sample preparation is of utmost importance. The main goals are to achieve the selective extraction of the analytes of interest and attain thorough matrix removal while retaining acceptable ecological properties, cost-effectiveness, and high throughput. Solid-phase extraction (SPE) offers a versatile range of options, from the selection of an appropriate sorbent to the optimisation of the washing and elution conditions. In this work, the first SPE method for the simultaneous extraction of six anticancer drugs used in novel therapeutic combinations for advanced breast cancer treatment—palbociclib, ribociclib, abemaciclib, anastrozole, letrozole, and fulvestrant—was developed. The following sorbent chemistries were tested: octylsilyl (C8), octadecylsilyl (C18), hydrophilic–lipophilic balance (HLB), mixed-mode cation-exchange (MCX and X-C), and mixed-mode weak cation-exchange (WCX), with different corresponding elution solvents. The samples were analysed using LC-MS/MS, with a phenyl column (150 × 4.6 mm, 2.5 μm). The best extraction recoveries (≥92.3%) of all analytes were obtained with the C8 phase, using methanol as the elution solvent. The optimised method was validated in the clinically relevant ranges, showing adequate precision (inter-day RSD ≤ 14.3%) and accuracy (inter-day bias −12.7–13.5%). Finally, its applicability was successfully proven by the analysis of samples from breast cancer patients.
- 12 October 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (10) , 1445
Open AccessOptimisation of Solid-Phase Extraction and LC-MS/MS Analysis of Six Breast Cancer Drugs in Patient Plasma Samples
In the development of bioanalytical LC-MS methods for the determination of drugs in plasma samples in a clinical setting, adequate sample preparation is of utmost importance. The main goals are to achieve the selective extraction of the analytes of interest and attain thorough matrix removal while retaining acceptable ecological properties, cost-effectiveness, and high throughput. Solid-phase extraction (SPE) offers a versatile range of options, from the selection of an appropriate sorbent to the optimisation of the washing and elution conditions. In this work, the first SPE method for the simultaneous extraction of six anticancer drugs used in novel therapeutic combinations for advanced breast cancer treatment—palbociclib, ribociclib, abemaciclib, anastrozole, letrozole, and fulvestrant—was developed. The following sorbent chemistries were tested: octylsilyl (C8), octadecylsilyl (C18), hydrophilic–lipophilic balance (HLB), mixed-mode cation-exchange (MCX and X-C), and mixed-mode weak cation-exchange (WCX), with different corresponding elution solvents. The samples were analysed using LC-MS/MS, with a phenyl column (150 × 4.6 mm, 2.5 μm). The best extraction recoveries (≥92.3%) of all analytes were obtained with the C8 phase, using methanol as the elution solvent. The optimised method was validated in the clinically relevant ranges, showing adequate precision (inter-day RSD ≤ 14.3%) and accuracy (inter-day bias −12.7–13.5%). Finally, its applicability was successfully proven by the analysis of samples from breast cancer patients.
- Open Access
Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
Advances in the treatment of HR+/HER2- breast cancer phenotype have been made with the introduction of abemaciclib, ribociclib, and palbociclib, inhibitors of cyclin D dependent kinases 4 and 6 (CDK4/6). Here, a novel, fast, cheap, and green CE method for the simultaneous determination of these three CDK4/6 inhibitors in less than 4 min is proposed for the first time. Separation was achieved by capillary zone electrophoresis in an acidic medium, in accordance with the structures of the analytes and their pKa values. The optimal pH of the running buffer was found to be 2.9. The optimal method conditions were 27.5 kV separation voltage, 30 °C, 5 s injection time under 50 mbar pressure, and 50 mM phosphate background buffer with benzimidazole as an internal standard. The developed method was validated with respect to robustness, selectivity, accuracy, precision, linearity, and limits of detection. The method was shown to be linear in the range of 10 to 100 µg mL−1 with correlation coefficients higher than 0.9981. A greenness assessment of the proposed method was performed, and the method was shown to be green. The validated method was successfully applied to pharmaceutical dosage forms of all CDK4/6 inhibitors.
Open AccessRapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
Advances in the treatment of HR+/HER2- breast cancer phenotype have been made with the introduction of abemaciclib, ribociclib, and palbociclib, inhibitors of cyclin D dependent kinases 4 and 6 (CDK4/6). Here, a novel, fast, cheap, and green CE method for the simultaneous determination of these three CDK4/6 inhibitors in less than 4 min is proposed for the first time. Separation was achieved by capillary zone electrophoresis in an acidic medium, in accordance with the structures of the analytes and their pKa values. The optimal pH of the running buffer was found to be 2.9. The optimal method conditions were 27.5 kV separation voltage, 30 °C, 5 s injection time under 50 mbar pressure, and 50 mM phosphate background buffer with benzimidazole as an internal standard. The developed method was validated with respect to robustness, selectivity, accuracy, precision, linearity, and limits of detection. The method was shown to be linear in the range of 10 to 100 µg mL−1 with correlation coefficients higher than 0.9981. A greenness assessment of the proposed method was performed, and the method was shown to be green. The validated method was successfully applied to pharmaceutical dosage forms of all CDK4/6 inhibitors.
- Open Access
- 3 October 2022
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 10, 999770
In a pursuit of optimal glycan fluorescent label for negative MS mode for high-throughput N-glycan analysis
Over the past few decades, essential role of glycosylation in protein functioning has become widely recognized, rapidly advancing glycan analysis techniques. Because free glycan’s lack chromophore or fluorophore properties, and do not ionize well, they are often derivatized to facilitate their separation or detection, and to enhance the sensitivity of the analysis. Released glycan’s are usually derivatized using a fluorescent tag, which enables their optical detection in LC profiling. Some fluorescent labels can also promote ionization efficiency, thus facilitating MS detection. For this reason, there is a need to design fluorophores that will contribute more to the fluorescence and ionization of glycan’s and the need to quantify these contributions to improve glycan analysis methods. In this paper we focused on negative MS mode as these methods are more informative than methods involving positive MS mode, allowing for a less ambiguous elucidation of detailed glycan structures. Additionally, traditional glycan labels in negative mode MS usually result with diminished sensitivity compared to positive mode, thus making selection of appropriate label even more important for successful high-throughput analysis. Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode. N-glycans released from IgG sample were labeled with one of the eleven labels, purified with HILIC-SPE and analyzed with HILIC-UPLC-FLR-MS. To make evaluation of studied labels performance more objective, analysis was performed in two laboratories and at two mobile phase pH (4.4 and 7.4). Although there was a notable trend of more hydrophobic labels having bigger signal intensities in one laboratory, we observed no such trend in the other laboratory. The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves. With this in mind, further research and development of fluorophores that will be suitable for high-throughput glycan analysis in the negative MS mode are proposed.
- 3 October 2022
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 10, 999770
Open AccessIn a pursuit of optimal glycan fluorescent label for negative MS mode for high-throughput N-glycan analysis
Over the past few decades, essential role of glycosylation in protein functioning has become widely recognized, rapidly advancing glycan analysis techniques. Because free glycan’s lack chromophore or fluorophore properties, and do not ionize well, they are often derivatized to facilitate their separation or detection, and to enhance the sensitivity of the analysis. Released glycan’s are usually derivatized using a fluorescent tag, which enables their optical detection in LC profiling. Some fluorescent labels can also promote ionization efficiency, thus facilitating MS detection. For this reason, there is a need to design fluorophores that will contribute more to the fluorescence and ionization of glycan’s and the need to quantify these contributions to improve glycan analysis methods. In this paper we focused on negative MS mode as these methods are more informative than methods involving positive MS mode, allowing for a less ambiguous elucidation of detailed glycan structures. Additionally, traditional glycan labels in negative mode MS usually result with diminished sensitivity compared to positive mode, thus making selection of appropriate label even more important for successful high-throughput analysis. Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode. N-glycans released from IgG sample were labeled with one of the eleven labels, purified with HILIC-SPE and analyzed with HILIC-UPLC-FLR-MS. To make evaluation of studied labels performance more objective, analysis was performed in two laboratories and at two mobile phase pH (4.4 and 7.4). Although there was a notable trend of more hydrophobic labels having bigger signal intensities in one laboratory, we observed no such trend in the other laboratory. The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves. With this in mind, further research and development of fluorophores that will be suitable for high-throughput glycan analysis in the negative MS mode are proposed.
- Open Access
- 3 October 2018
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 68 (4) , 471-483
Chloroquine Urea Derivatives: Synthesis and Antitumor Activity in Vitro
In the current paper, we describe the design, synthesis and antiproliferative screening of novel chloroquine derivatives with a quinoline core linked to a hydroxy or halogen amine through a flexible aminobutyl chain and urea spacer. Synthetic pathway leading to chloroquine urea derivatives 4-10 includes two crucial steps: i) synthesis of chloroquine benzotriazolide 3 and ii) formation of urea derivatives through the reaction of compound 3 with the corresponding amine. Testing of antiproliferative activity against four human cancer cell lines revealed that chloroquine urea derivatives 9 and 10 with aromatic moieties show activity at micromolar concentrations. Therefore, these molecules represent interesting lead compounds that might provide an insight into the design of new anticancer agents.
- 3 October 2018
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 68 (4) , 471-483
Open AccessChloroquine Urea Derivatives: Synthesis and Antitumor Activity in Vitro
In the current paper, we describe the design, synthesis and antiproliferative screening of novel chloroquine derivatives with a quinoline core linked to a hydroxy or halogen amine through a flexible aminobutyl chain and urea spacer. Synthetic pathway leading to chloroquine urea derivatives 4-10 includes two crucial steps: i) synthesis of chloroquine benzotriazolide 3 and ii) formation of urea derivatives through the reaction of compound 3 with the corresponding amine. Testing of antiproliferative activity against four human cancer cell lines revealed that chloroquine urea derivatives 9 and 10 with aromatic moieties show activity at micromolar concentrations. Therefore, these molecules represent interesting lead compounds that might provide an insight into the design of new anticancer agents.
- Open Access
- 21 August 2018
- Published by Wiley in ChemistryOpen
- Vol. 7 (8) , 624-638
SAHAquines, Novel Hybrids Based on SAHA and Primaquine Motifs, as Potential Cytostatic and Antiplasmodial Agents
We report the synthesis of SAHAquines and related primaquine (PQ) derivatives. SAHAquines are novel hybrid compounds that combine moieties of suberoylanilide hydroxamic acid (SAHA), an anticancer agent with weak antiplasmodial activity, and PQ, an antimalarial drug with low antiproliferative activity. The preparation of SAHAquines is simple, cheap, and high yielding. It includes the following steps: coupling reaction between primaquine and a dicarboxylic acid monoester, hydrolysis, a new coupling reaction with O‐protected hydroxylamine, and deprotection. SAHAquines 5 a–d showed significant reduction in cell viability. Among the three human cancer cell lines (U2OS, HepG2, and MCF‐7), the most responsive were the MCF‐7 cells. The antibodies against acetylated histone H3K9/H3K14 in MCF‐7 cells revealed a significant enhancement following treatment with N‐hydroxy‐N′‐{4‐[(6‐methoxyquinolin‐8‐yl)amino]pentyl}pentanediamide (5 b). Ethyl (2E)‐3‐({4‐[(6‐methoxyquinolin‐8‐yl)amino]pentyl}carbamoyl)prop‐2‐enoate (2 b) and SAHAquines were the most active compounds against both the hepatic and erythrocytic stages of Plasmodium parasites, some of them at sub‐micromolar concentrations. The results of our research suggest that SAHAquines are promising leads for new anticancer and antimalarial agents.
- 21 August 2018
- Published by Wiley in ChemistryOpen
- Vol. 7 (8) , 624-638
Open AccessSAHAquines, Novel Hybrids Based on SAHA and Primaquine Motifs, as Potential Cytostatic and Antiplasmodial Agents
We report the synthesis of SAHAquines and related primaquine (PQ) derivatives. SAHAquines are novel hybrid compounds that combine moieties of suberoylanilide hydroxamic acid (SAHA), an anticancer agent with weak antiplasmodial activity, and PQ, an antimalarial drug with low antiproliferative activity. The preparation of SAHAquines is simple, cheap, and high yielding. It includes the following steps: coupling reaction between primaquine and a dicarboxylic acid monoester, hydrolysis, a new coupling reaction with O‐protected hydroxylamine, and deprotection. SAHAquines 5 a–d showed significant reduction in cell viability. Among the three human cancer cell lines (U2OS, HepG2, and MCF‐7), the most responsive were the MCF‐7 cells. The antibodies against acetylated histone H3K9/H3K14 in MCF‐7 cells revealed a significant enhancement following treatment with N‐hydroxy‐N′‐{4‐[(6‐methoxyquinolin‐8‐yl)amino]pentyl}pentanediamide (5 b). Ethyl (2E)‐3‐({4‐[(6‐methoxyquinolin‐8‐yl)amino]pentyl}carbamoyl)prop‐2‐enoate (2 b) and SAHAquines were the most active compounds against both the hepatic and erythrocytic stages of Plasmodium parasites, some of them at sub‐micromolar concentrations. The results of our research suggest that SAHAquines are promising leads for new anticancer and antimalarial agents.